ArticleBritish journal of biomedical science2026
Concordance between crude extract and component allergens in a multiple allergen simultaneous test: a large-scale retrospective analysis.
Article in British journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Multiple allergen simultaneous tests (MAST) increasingly incorporate both crude extract and molecular component allergens for specific IgE testing. However, systematic data on the diagnostic concordance between these two approaches remain limited. We evaluated the agreement between crude extract and corresponding component allergen results using a MAST panel in a large clinical laboratory cohort. Methods: We retrospectively analysed deduplicated MAST results from a high-volume referral laboratory over a two-month period. For 29 crude extract allergens paired with 48 corresponding component allergens, positivity rates were assessed using a cutoff of class 2 or higher (≥0.70 IU/mL). Concordance was defined as both crude extract and at least one component allergen being positive, or both being negative. Agreement was evaluated using percent agreement and Cohen's kappa coefficient. Results: A total of 19,949 patients were included. The highest positivity rates were observed for Conclusion: Diagnostic concordance between crude extract and component allergen testing in MAST varies substantially across allergen sources. These findings underscore the need for allergen-specific interpretation guidelines when reporting MAST results incorporating component allergens in clinical laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.